Medicenna Therapeutics (TSE:MDNA) Issues Earnings Results

Medicenna Therapeutics (TSE:MDNA) issued its earnings results on Thursday. The company reported C($0.05) earnings per share for the quarter, FiscalAI reports. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 159.88%.

Medicenna Therapeutics Price Performance

Medicenna Therapeutics stock remained flat at C$0.76 during trading hours on Thursday. The company’s stock had a trading volume of 18,278 shares, compared to its average volume of 121,261. The firm’s 50-day moving average price is C$0.98 and its 200 day moving average price is C$1.10. The company has a debt-to-equity ratio of 0.88, a current ratio of 11.40 and a quick ratio of 4.65. The firm has a market capitalization of C$63.39 million, a PE ratio of -4.47 and a beta of 2.87. Medicenna Therapeutics has a twelve month low of C$0.74 and a twelve month high of C$1.97.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.